IMPEDIMED LIMITED (IPD)
Share Price Analysis and Chart

Enter the company code or Name for stock analysis:

IPD

IPD - IMPEDIMED LIMITED

FNArena Sector : Medical Equipment & Devices
Year End: June
GICS Industry Group : Health Care Equipment & Services
Debt/EBITDA: -0.05
Index:

LAST PRICE CHANGE +/- CHANGE % VOLUME

$0.034

05 May
2025

-0.005

OPEN

$0.04

-12.82%

HIGH

$0.04

1,460,831

LOW

$0.03

TARGET
$0.135 297.1% upside
OTHER COMPANIES IN THE SAME SECTOR
4DX . AT1 . AYA . BB1 . BRN . CAT . CBL . CGS . CMP . COH . CSX . CU6 . CVB . CYC . EBR . EMV . EYE . FPH . IDX . IME . IMR . LDX . MX1 . NAN . ONE . PCK . PEB . PGC . PME . RMD . SOM . TRJ . UBI .
FNARENA'S MARKET CONSENSUS FORECASTS
IPD: 1
Title FY23
Actual		 FY24
Actual		 FY25
Forecast		 FY26
Forecast
EPS (cps) xxx - 1.0 - 0.8 xxx
DPS (cps) xxx 0.0 0.0 xxx
EPS Growth xxx N/A N/A xxx
DPS Growth xxx N/A N/A xxx
PE Ratio xxx N/A N/A xxx
Dividend Yield xxx N/A 0.0% xxx
Div Pay Ratio(%) xxx N/A N/A xxx

Dividend yield today if purchased 3 years ago: 0.00%

DIVIDEND YIELD CALCULATOR

Dividend Yield Today On Last Actual Payout :

 0.00

Estimated Dividend Growth
(Average Of Past Three Years)

  %

Amount Invested

 $ 

Tell Me The Dividend After This Many Years
Past performance is no guarantee for the future. Investors should take into account that heavy swings in share price or exceptional circumstances (a la 2009) can have a significant impact on short term calculations and averages
HISTORICAL DATA ARE ALL IN AUD
Copyright © 2025 FactSet UK Limited. All rights reserved
Title 201920202021202220232024
EPS Basic xxxxxxxxxxxxxxx-1.0
DPS All xxxxxxxxxxxxxxx0.0
Sales/Revenue xxxxxxxxxxxxxxx10.3 M
Book Value Per Share xxxxxxxxxxxxxxx2.0
Net Operating Cash Flow xxxxxxxxxxxxxxx-17.8 M
Net Profit Margin xxxxxxxxxxxxxxx-191.78 %

EPS Basic

DPS All

Sales/Revenue

Book Value Per Share

Net Operating Cash Flow

Net Profit Margin

Title 201920202021202220232024
Return on Capital Employed xxxxxxxxxxxxxxx-38.95 %
Return on Invested Capital xxxxxxxxxxxxxxx-38.21 %
Return on Assets xxxxxxxxxxxxxxx-34.20 %
Return on Equity xxxxxxxxxxxxxxx-38.95 %
Return on Total Capital xxxxxxxxxxxxxxx-46.01 %
Free Cash Flow ex dividends xxxxxxxxxxxxxxx-17.9 M

Return on Capital Employed

Return on Invested Capital

Return on Assets

Return on Equity

Return on Total Capital

Free Cash Flow ex dividends

Title 201920202021202220232024
Short-Term Debt xxxxxxxxxxxxxxx0 M
Long Term Debt xxxxxxxxxxxxxxx1 M
Total Debt xxxxxxxxxxxxxxx1 M
Goodwill - Gross xxxxxxxxxxxxxxx3 M
Cash & Equivalents - Generic xxxxxxxxxxxxxxx25 M
Price To Book Value xxxxxxxxxxxxxxx3.57

Short-Term Debt

Long Term Debt

Total Debt

Goodwill - Gross

Cash & Equivalents - Generic

Price To Book Value

Title 201920202021202220232024
Capex xxxxxxxxxxxxxxx3.1 M
Capex % of Sales xxxxxxxxxxxxxxx30.09 %
Cost of Goods Sold xxxxxxxxxxxxxxx24 M
Selling, General & Admin. Exp & Other xxxxxxxxxxxxxxx10 M
Research & Development xxxxxxxxxxxxxxx0 M
Investments - Total xxxxxxxxxxxxxxx0 M

Capex

Capex % of Sales

Cost of Goods Sold

Selling, General & Admin. Exp & Other

Research & Development

Investments - Total

EXPERT VIEWS
Display All Commentary

Sentiment Indicator

1.0

No. Of Recommendations

2
BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Morgans

xx/xx/xxxx

1

xxxxxxxxxxx xxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Ord Minnett

03/02/2025

1

Speculative Buy

$0.12

252.94%

ImpediMed’s 2Q result was mixed, according to Ord Minnett, with revenue of $3.3m, free cash flow of -$2.6m, and payor coverage of 259m lives exceeding expectations, while US SOZO sales fell short at 20 units versus 28 in the first quarter.

The broker remains encouraged by ongoing lead pipeline growth, expanding private payor coverage, and strong pricing tailwinds, but awaits a clearer acceleration in US sales.

Key near-term catalysts include contract wins and material payor updates, suggest the analysts. The target price is lowered to 12c from 13c, with a Speculative Buy rating retained.

FORECAST
Ord Minnett forecasts a full year FY25 dividend of 0.00 cents and EPS of minus -0.80 cents.
Ord Minnett forecasts a full year FY26 dividend of 0.00 cents and EPS of minus -0.40 cents.
Access Stockbroker Research History >
EXTRA COVERAGE
Display All Commentary

No. Of Recommendations

2

Please note: unlike Broker Call Report, BC Extra is not updated daily. The info you see might not be the latest. FNArena does its best to update ASAP.

BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Canaccord Genuity

xx/xx/xxxx

1

xxxxxxxxxxx xxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Wilsons

05/02/2025

1

Overweight

$0.17

400.00%

ImpediMed's 2Q25 revenue missed Wilsons' estimate by -$0.3m but the key focus for the broker was the reimbursement update. The analyst is impressed by the addition of 112m covered lives, with the total surpassing the 250m mark (258.5m)

Underlying cash outflow was consistent with the guidance at $3.4m and with $17.7m cash, ImpediMed is fully funded through to achieving break-even, the broker highlights.  

No change to forecasts but the broker will reassess its estimates following 1H25 results to be released on Feb 27. Target price of 17c and Overweight rating are unchanged.

FORECAST
Wilsons forecasts a full year FY25 dividend of 0.00 cents and EPS of minus -0.80 cents.
Wilsons forecasts a full year FY26 dividend of 0.00 cents and EPS of minus -0.60 cents.
Access Extra Coverage Research History >

IPD STOCK CHART

FNArena News on IPD

1
Australian Broker Call *Extra* Edition – May 05, 2025

May 05 2025 - Daily Market Reports
2
FNArena Corporate Results Monitor – 05-03-2025

Mar 05 2025 - Australia
3
Rudi’s View: Earnings Optimism On The Rise

Feb 05 2025 - Rudi's View
4
Australian Broker Call *Extra* Edition – Feb 05, 2025

Feb 05 2025 - Daily Market Reports
5
Australian Broker Call *Extra* Edition – Oct 28, 2024

Oct 28 2024 - Daily Market Reports

Latest Medical Equipment & Devices News

1
ResMed’s Margin Expansion & Tariff Exemption

Apr 28 2025 - Australia
2
Trend Remains Up For Catapult International

Feb 18 2025 - Technicals
3
ESG Focus: Top ASX Companies, Superbugs & Hydrogen

Feb 07 2025 - ESG Focus
4
ResMed Shakes Off GLP-1 Scare

Feb 04 2025 - Australia
5
ResMed: Another Positive Quarterly Surprise?

Jan 30 2025 - Australia
6
The Trend Remains Pro Medicus’ Friend

Jan 16 2025 - Technicals
7
Diagnostic Imaging Radiates Opportunity

Dec 18 2024 - Small Caps
8
ResMed’s Bounce-Back Complete

Oct 29 2024 - Australia
9
Dr Boreham’s Crucible: Pro Medicus

Sep 04 2024 - Australia
10
Pro Medicus: Don’t Stop Me Now

Aug 20 2024 - Technicals